Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Falsified Mounjaro pens prompt urgent safety advisory MHRA warns of counterfeit Mounjaro pens (batch D873576)
Schedule a consultation with our expert providers to discuss your aesthetic needs
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
This may take two to five minutes for complete dissolution
muciniphila strains isolated from adult humans and laboratory mice and identified three major phylogroups using maximum likelihood phylogenetic analysis